192 related articles for article (PubMed ID: 19170413)
21. Current concepts and review of efalizumab in the treatment of psoriasis.
Leonardi CL
Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
[TBL] [Abstract][Full Text] [Related]
22. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
23. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Puig L; Roé E; García-Navarro X; Corella F; Alomar A
Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
[TBL] [Abstract][Full Text] [Related]
24. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
26. Efalizumab.
Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
Pariser DM; Gordon KB; Papp KA; Leonardi CL; Kwon P; Compton PG; Rundle AC; Walicke PA; Lebwohl M
J Cutan Med Surg; 2005 Dec; 9(6):303-12. PubMed ID: 16699904
[TBL] [Abstract][Full Text] [Related]
28. [Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice].
Dirschka T; Reinhold U; Rosenbach T; Schubert E; Sebastian M; Streit V
J Dtsch Dermatol Ges; 2006 Oct; 4 Suppl 1():S3-S12. PubMed ID: 17022742
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial.
Lotti T; Chimenti S; Katsambas A; Ortonne JP; Dubertret L; Licu D; Simon J
Arch Drug Inf; 2010 Mar; 3(1):9-18. PubMed ID: 20428228
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
Toth DP; Papp K; Gratton D
Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
[TBL] [Abstract][Full Text] [Related]
32. Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.
Papp KA
Drugs Today (Barc); 2004 Nov; 40(11):889-99. PubMed ID: 15645002
[TBL] [Abstract][Full Text] [Related]
33. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program.
Foley P; Freeman M; Gebauer K; Murrell D; Shumack S; Tyson C; Varigos G
Int J Dermatol; 2009 Dec; 48(12):1376-84. PubMed ID: 19930495
[TBL] [Abstract][Full Text] [Related]
34. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
35. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
[TBL] [Abstract][Full Text] [Related]
36. Case reports: practical experience with efalizumab in hand and foot psoriasis.
Cohen DJ; Scherschun L
J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
[TBL] [Abstract][Full Text] [Related]
37. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
38. Efalizumab: a review of events reported during clinical trials and side effects.
Scheinfeld N
Expert Opin Drug Saf; 2006 Mar; 5(2):197-209. PubMed ID: 16503742
[TBL] [Abstract][Full Text] [Related]
39. [The lymphocyte: protagonism in the new era of the biological therapies].
Gutiérrez M; Ruiz Carrascosa JC
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
[TBL] [Abstract][Full Text] [Related]
40. Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients.
Brunasso AM; Salvini C; Massone C
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):415-9. PubMed ID: 19207662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
